Loading...

PRPL

PPBT

PURPLE BIOTECH LTD

(PPBT)

2025 6-K

Summary

Summary

Manufacturing Milestone

29 Oct '25

Extraordinary Meeting Notice

28 Oct '25

ATM Offering Agreement

19 Sep '25

Company Presentation Update

15 Sep '25

Patent Grant Intent

10 Sep '25

New Public Offering

5 Sep '25

New Data Announcement

4 Sep '25

New Antibody Expansion

3 Sep '25

Financial Results Report

6 Aug '25

CEO Pipeline Update

23 Jul '25

Updated Presentation

10 Jul '25

Press Release Highlights

23 Jun '25

Phase 2 Study Initiated

17 Jun '25

Quarterly Results

21 May '25

Management Change

12 May '25

Company Presentation Update

6 May '25

Phase 2 Study Results

30 Apr '25

Positive Data Report

28 Apr '25

Shareholder Meeting Results

22 Apr '25

Research Publication

16 Apr '25

Annual Meeting Update

15 Apr '25

Panel Discussion Announcement

1 Apr '25

Presentation Announcement

28 Mar '25

Company Presentation Update

18 Mar '25

Filing Amendment

10 Mar '25

Financial Results Announced

10 Mar '25

Patent Granted

5 Mar '25

Shareholder Meeting Notice

28 Feb '25

Clinical Trial Update

18 Feb '25

Research Collaboration

3 Feb '25

Fundraising Update

6 Jan '25

Company Update

6 Dec '24

Funding Announcement

5 Dec '24

Securities Report

4 Dec '24

Funding Announcement

3 Dec '24

Positive Study Results

2 Dec '24

Financial Results Release

15 Nov '24

Biomarker Identification

4 Nov '24

New Data Release

25 Oct '24

Data Presentation Update

10 Oct '24

Updated Presentation

9 Oct '24

Compliance Regained

2 Oct '24

Positive Data Release

18 Sep '24

ADS Ratio Change

11 Sep '24

Company Presentation Update

19 Aug '24

Financial Results Report

16 Aug '24

Meeting Results

8 Aug '24

Management Change

5 Aug '24

Compliance Extension

25 Jul '24

Company Presentation Update

19 Jul '24

Warrants Exercise

2 Jul '24

Warrant Repricing Report

2 Jul '24

Warrant Exercise Announcement

1 Jul '24

Positive Study Results

27 Jun '24

Annual Meeting Notice

26 Jun '24

Lawsuit Dismissed

20 Jun '24

Company Update

4 Jun '24

Phase 2 Data Release

3 Jun '24

Financial Results Report

21 May '24

Company Update

2 May '24

Study Presentation Announce...

25 Apr '24

Oncology Drug Presentation

28 Mar '24

Research Progress

14 Mar '24

Company Presentation Update

6 Mar '24

Financial Results Report

5 Mar '24

Data Presentation

27 Feb '24

Cancer Advisory Board

13 Feb '24

Phase 2 Dose Announcement

1 Feb '24

Nasdaq Notification

26 Jan '24

External Links:

SEC

On September 4, 2025, Purple Biotech Ltd. announced new data for its CAPTN-3 tri-specific antibody IM1240, developed in collaboration with the Icahn School of Medicine at Mount Sinai. This filing is significant for investors as it highlights advancements in the company’s research and development.

AI Assistant

PURPLE BIOTECH LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.